Baudax Bio, Inc.: Nasdaq/NYSE listing notice — Baudax Bio receives Nasdaq delisting notice; suspension Nov 16

Baudax Bio, Inc.

Nasdaq Panel determined to delist BXRX common stock for failure to meet initial listing requirements by Nov 13, 2023.
Trading suspension on Nasdaq Capital Market effective at opening on November 16, 2023.
Company has 15 days to request a review by the Nasdaq Listing and Hearing Review Council.
If no timely request, Form 25-NSE will be filed removing securities from Nasdaq registration.
Stock may become eligible for OTC trading, but no assurance is given.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Baudax Bio, Inc. received a nasdaq delisting notice notice regarding other (rules 5550(b)(1), 5550(a)(2)).

Exchange: nasdaq
Notice: delisting notice
Rules: 5550(b)(1), 5550(a)(2)

Exact text from the filing

November 14, 2023, the Company received a determination letter (the “Delisting Notification”) from the Nasdaq Hearings Advisor stating that the Panel has determined to delist the Company’s common stock, par value $0.01 per share (the “Common Stock”) from the Nasdaq Capital Market, and Nasdaq will accordingly suspend trading in the Company’s Common Stock, effective at the opening of trading on November 16, 2023, because the Company did not demonstrate compliance initial listing requirements by November 13, 2023. Pursuant to the Delisting Notification, the Company has a period of 15 days from th

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001193125-23-277889

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.